Fosbretabulin: Preliminary Phase Ib data

Preliminary data from 9 evaluable patients with advanced recurrent ovarian cancer in the dose-escalation Phase Ib portion of the open-label, U.K. Phase Ib/II PAZOFOS trial showed that once-weekly 45-6...